Jefferies lowered the firm’s price target on Alexandria Real Estate (ARE) to $47 from $62 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. Landlords have limited negotiating leverage, and the firm’s market forecast suggests this will persist for several years, Jefferies added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARE:
- Alexandria Equities Announces New Stock Repurchase Program
- Alexandria Real Estate refreshes, extends $500M stock repurchase program
- Alexandria Real Estate price target lowered to $50 from $57 at BofA
- Alexandria Real Estate price target lowered to $48 from $52 at Cantor Fitzgerald
- Alexandria Real Estate price target lowered to $64 from $72 at Evercore ISI